Fig. 7.

Lack of VRC01 self-reactivity. (A) Reactivity of MAbs 2F5, 17b, and VRC01 with human HEp-2 epithelial cells. The MAb 2F5 served as a positive control and reacted in a diffuse cytoplasmic and nuclear pattern. (B) Luminex AtheNA Multi-Lyte ANA test for a panel of nuclear antigens: systemic lupus erythematosus autoantigens SSA and SSB, sphingomyelin (Sm), ribonucleoprotein (RNP), sclerosis autoantigen (Scl-70), histidine-tRNA ligase (Jo-1), double-stranded DNA (dsDNA), and centromere B (CentB). (C) The clinical assay, activated partial thromboplastin time (aPTT), was used to assess potential antiplatelet, antiphospholipid activity. The MAbs were added to normal sera, and the time to clot formation was measured. The clotting times for VRC01, VRC02, VRC03, b12, and the anti-RSV monoclonal antibody Synagis (palivizumab) were all in the normal range. In contrast, the known polyreactive MAb 4E10 caused a prolongation of the aPTT.